Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease

Affiliations

• ¹ Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, New York, USA; ASL Avellino, Italy; University of Molise, Campobasso, Italy.
• ² University of Molise, Campobasso, Italy; International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Naples, Italy.
• ³ Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, New York, USA.
• ⁴ "Federico II" University, Naples, Italy.
• ⁵ ASL Avellino, Italy.
• ⁶ University of Bari, Italy.
• ⁷ Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy.
• ⁸ "Federico II"University, Naples, Italy.
• ⁹ Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy; International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Naples, Italy; Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, New York, USA; Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, New York City, New York 10461, USA. Electronic address: [email protected].